Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR Platform in Immunology-Based Diseases at AAI Annual Meeting

PREDATOR protein engineering technology allows for the expansion of INDUKINE molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory bowel disease

WATERTOWN, Mass., April 04, 2024 (GLOBE NEWSWIRE) --  Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the publication of an abstract for an upcoming poster presentation at IMMUNOLOGY^TM 2024, the annual meeting of the American Association of Immunologists (AAI) taking place May 3-7 in Chicago, Illinois.

“We are thrilled to be attending and presenting for the first time at AAI to highlight the data supporting the potential of our novel platform in immunology-based diseases beyond cancer,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. “While our core focus remains rooted in oncology, we understand that the biology driving our PREDATOR platform is also capable of targeting immunology targets, and this data validates the potential utility in broader therapeutic areas. It’s a pivotal moment as we step into the immunology landscape, ready to showcase our innovative contributions and engage with fellow leaders in the field.”

Details for the poster presentation is as follows:

Title: Development of conditionally active IL-10 INDUKINE^TM molecules for the treatment of inflammatory bowel disease
Session Date and Time: Monday, May 6, 2024, from 2:15 p.m. – 3:30 p.m. CT
Board Number: B906

To learn more about our platform and immunology approach, visit www.werewolftx.com.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We expect to advance WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com.